Literature DB >> 20620589

A novel case of t(X;1)(p11.2;p34) in a renal cell carcinoma with TFE3 rearrangement and favorable outcome in a 57-year-old patient.

Juliette Haudebourg1, Benjamin Hoch, Thibault Fabas, Fanny Burel-Vandenbos, Xavier Carpentier, Jean Amiel, Nathalie Cardot-Leccia, Jean-François Michiels, Florence Pedeutour.   

Abstract

Renal cell carcinoma (RCC) with translocation involving Xp11.2 (Xp11.2-RCC) is a rare neoplasm that usually occurs in children and young adults. This incidence is underestimated in adults because its morphological similarities with clear-cell RCC or papillary RCC2,3, as well as immunohistochemical and cytogenetic analyses are not carried out systematically in adults. We present a novel case of Xp11.2-RCC in a 57-year-old woman. The histologic features were those of a clear-cell RCC. Molecular cytogenetic analysis showed an uncommon t(X;1)(p11.2;p34) with TFE3 rearrangement and no alteration of chromosome 3. The immunohistochemical analysis showed expression of the TFE3 protein. Only nine cases of (X;1)(p11.2;p34) have been published, most of them occurring in children or young adults. To our knowledge, this is the second report of such a translocation in a patient older than 55 years. After a follow-up period of 13 months, the patient showed no evidence of disease. The clinical outcome was favorable, indicating that this particular translocation might be associated with a good prognosis. This observation confirms that Xp11.2-RCC are very likely to be underestimated in adults older than 40 years, and it highlights the importance of performing immunohistochemical and cytogenetic analyses in RCC for accurate diagnosis. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620589     DOI: 10.1016/j.cancergencyto.2010.03.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

Review 2.  MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.

Authors:  Audrey Simonaggio; Damien Ambrosetti; Virginie Verkarre; Marie Auvray; Stéphane Oudard; Yann-Alexandre Vano
Journal:  Int J Mol Sci       Date:  2022-07-11       Impact factor: 6.208

3.  Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.

Authors:  Yuqing Wu; Saisai Chen; Minhao Zhang; Kuangzheng Liu; Jibo Jing; Kehao Pan; Lihua Zhang; Bin Xu; Xiaoming Lu; Ming Chen
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

4.  Xp11 Translocation Renal Cell Carcinoma: Unusual Variant Masquerading as Upper Tract Urothelial Cell Carcinoma.

Authors:  Arash Akhavein; Julia Han; Christopher Carter; Samer Z Al-Quran; Li-Ming Su
Journal:  Urol Case Rep       Date:  2014-03-31

Review 5.  Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: an adult case report and literature review.

Authors:  Yuxiong Wang; Yuantao Wang; Mingliang Feng; Xin Lian; Yongsheng Lei; Honglan Zhou
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.